Skip to main content
SpringerLink
Log in

Caf versus caf plus medroxyprogesterone acetate for treatment of liver metastases of breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

A controlled randomized trial was conducted to compare the effectiveness of a CAF therapy including cyclophosphamide (CPA), adriamycin (ADR) and 5-fluor-ouracil (5FU) with that of CAF plus medroxyprogesterone acetate (MPA) therapy including CPA, ADR and 5FU plus MPA for the treatment of liver metastases from breast cancer. A total of 34 patients with unresectable liver metastases from breast cancer were divided into two treatment groups (CAF and CAF + MPA) with stratification for estrogen receptor status. The response rate was 13% (2 PR in 16 patients) for CAF therapy and 22% (1 CR and 3 PR in 18 patients) for CAF plus MPA therapy. There was no significant difference in response rates, median survival periods and survival rates between the two treatment groups. However, CAF therapy had significantly more toxicity than did CAF plus MPA therapy. The findings of this study suggested that CAF plus MPA therapy is a well-tolerated and effective treatment for patients with liver metastases of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ADR:

Adriamycin

CPA:

Cyclophosphamide

ER:

Estrogen receptor

5FU:

5-Fluorouracil

MPA:

Medroxyprogesterone acetate

References

  1. Henderson IC: Chemotherapy for metastatic diseases. In: Harris JR, Henderson IC, Kinne DW eds, Breast Diseases, 2nd ed, JB Lippincott, Philadelphia, pp604- 665, 1991.

    Google Scholar 

  2. Zinser JW, Hortogagyi GN, Buzdar AU,et al: Clinical course of breast cancer patients with liver metastases.J Clin Oncol 5:773–782, 1987.

    PubMed  CAS  Google Scholar 

  3. Bonadonna G, Valagussa P: Chemotherapy of breast cancer; Current views and results.Int J Rad Oncol Biol Phys 9:279–297, 1983.

    CAS  Google Scholar 

  4. Carter SK: Single and combination nonhormonal chemotherapy in breast cancer.Cancer 30:1543–1555, 1972.

    Article  PubMed  CAS  Google Scholar 

  5. Inoue K, Ogawa M, Horikoshi N,et al: Clinical features and chemotherapy of breast cancer patients with liver metastases.J Jpn Soc Cancer Ther 27: 646 -653, 1992 (in Japanese with English summary).

    Google Scholar 

  6. Shimozuma K, Tominaga T, Kosaki K: Characteristics and treatments for liver metastasis from breast cancer.J Jpn Soc Cancer Ther 26:1087–1094, 1991 (in Japanese with English summary).

    Google Scholar 

  7. Inoue K, Ogawa M, Horikoshi N,et al: Evaluation of prognostic factors in 233 patients with recurrent advanced breast cancer.Jpn J Clin Oncol 21:334–339, 1991.

    PubMed  CAS  Google Scholar 

  8. Poulin B, Baker D, Poirier D,et al: Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.Breast Cancer Res Treat 12:213–225, 1988.

    Article  PubMed  CAS  Google Scholar 

  9. Wagner RK, Jungbult PW: Oestradiol and dihydrotestosterone receptors in normal and neoplastic human mammary tissue.Acta Endocrinol 82:105–120, 1976.

    PubMed  CAS  Google Scholar 

  10. Focan C, Baudoux A, Beauduin U,et al: Improvement of hematological and general tolerance to CMF by high-dose medroprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients).Anticancer Res 6: 1095–1100, 1986.

    PubMed  CAS  Google Scholar 

  11. Gundersen S, Kvinnsland S, Klepp O,et al: Chemotherapy with or without high-dose medroxyprogester-one acetate in oestrogen receptor-negative advanced breast cancer.Eur J Cancer 28:390–394, 1992.

    Article  PubMed  CAS  Google Scholar 

  12. Furue H, Hara Y, Imai Y,et al: Criteria for the evaluation of direct effects of solid cancer chemotherapy.J Jpn Soc Cancer Ther 28:105–118, 1993.

    Google Scholar 

  13. Tobinai K, Kohno A, Shimada Y,et al. Toxicity grading criteria of the Japan Clinical Oncology Group.Jpn J Clin Oncol 23:250–257, 1993.

    PubMed  CAS  Google Scholar 

  14. Kemeny N: The systemic chemotherapy of hepatic metastases.Semin Oncol 10:148–158, 1983.

    PubMed  CAS  Google Scholar 

  15. Smalley RV, Carpenters J, Vogel C,et al. A comparison of cyclophosphamide, adriamycin and 5-fluorour- acil (CAF) and cyclophosphamide, methotrexate, 5- fluorouracil, vincristine, and prednisolone (CMFVP) in patients with metastatic breast cancers.Cancer 40: 625–630, 1977.

    Article  PubMed  CAS  Google Scholar 

  16. Inoue K, Ogawa M, Inagaki J,et al. A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer.Cancer Chemother Pharmacol 13:95–99, 1984.

    Article  PubMed  CAS  Google Scholar 

  17. Wada T, Koyama H, Yasutomi M,et al. Conventional dose CAF therapy versus low dose adriamycin therapy in the treatment of advanced breast cancer.Breast Cancer 1:51–56, 1994.

    Article  PubMed  Google Scholar 

  18. Wada T, Houjou T, Morikawa E,et al. Combination therapy with medroxyprogesterone acetate and tegafur for tamoxifen- and adriamycin-resistant advanced breast cancers.Jpn J Cancer Chemother 16: 2087–2092, 1989 (in Japanese with English summary).

    CAS  Google Scholar 

  19. Ohnishi S, Murakami T, Moriyama T: Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue.Hepatology 6:440–443, 1986.

    Article  PubMed  CAS  Google Scholar 

  20. Nagasue N, Yutaka H, Ito H: Estrogen receptor in hepatocellular carcinoma.Cancer 57:87–91, 1986.

    Article  PubMed  CAS  Google Scholar 

  21. Mattsson W: Current status of high dose progestin treatment in advanced breast cancer.Breast Cancer Res Treat 3:231–235, 1983.

    Article  PubMed  CAS  Google Scholar 

  22. Haller DG, Glick JH: Progestational agents in advanced breast cancer; An overview.Semin Oncol 13:2–8, 1986.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Surgery, Kinki University, 377, Ohnohigashi, 589, Osaka-Sayama, Japan

    Tomio Wada, Kouichiro Nishiyama, Yoshihiro Nakatani, Toshiya Houjou, Hiroki Inui, Eiju Yamauchi, Satoshi Hara & Masayuki Yasutomi

  2. First Department of Surgery, Kinki University School of Medicine, 377, Ohnohigashi, 589, Osaka-Sayama, Japan

    Tomio Wada, Kouichiro Nishiyama, Yoshihiro Nakatani, Toshiya Houjou, Hiroki Inui, Eiju Yamauchi, Satoshi Hara & Masayuki Yasutomi

Authors
  1. Tomio Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kouichiro Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiro Nakatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiya Houjou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroki Inui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiju Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masayuki Yasutomi
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Wada, T., Nishiyama, K., Nakatani, Y. et al. Caf versus caf plus medroxyprogesterone acetate for treatment of liver metastases of breast cancer. Breast Cancer 2, 65–70 (1995). https://doi.org/10.1007/BF02966898

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966898

Key words

Search

Navigation